Traditional MedicareCoverageMedium impact
Erythropoiesis Stimulating Agents
Medicare/CMS - LCD·Nephrology, Oncology, Hematology·Local Coverage Determination
Effective date
Jul 15, 2026
We identified it
Jun 17, 2026
Summary
A new Local Coverage Determination for Erythropoiesis Stimulating Agents (ESAs) will take effect July 15, 2026, replacing previous coverage guidelines. This policy determines Medicare coverage criteria for ESA medications used to treat anemia, particularly in patients with chronic kidney disease or cancer.
Action Required
Before July 15, 2026: Billing team must review the complete LCD L40334 policy text to identify specific coverage criteria, documentation requirements, and billing guidelines for Erythropoiesis Stimulating Agents. Update billing protocols and provider documentation templates accordingly. Monitor CMS website for the full policy details as the effective date approaches.